Navigation Links
Aratana Therapeutics Completes $15 Million Series B Financing
Date:12/7/2011

KANSAS CITY, Kan., Dec. 7, 2011 /PRNewswire/ -- Aratana Therapeutics, an animal health company developing innovative medicines for companion animals, announced today the closing of a $15 million Series B financing, bringing the total capital raised since Aratana was launched earlier this year to $31 million.

In addition to Aratana's Series A investors – MPM Capital, Avalon Ventures and Cultivian Ventures – new investors include the Ewing Marion Kauffman Foundation and others. 

The proceeds from the Series B financing will be used to expand the rich pipeline of innovative products that the company has already acquired.  The additional resources allow for a more aggressive approach to in-license and develop novel medicines for dogs and cats. 

"We are extremely pleased that the investment community has responded so positively to our unique approach to veterinary drug development and our focus on delivering innovative, leading-edge products to meet previously unmet or under-served needs in companion animal medicine," said Dr. Linda Rhodes, CEO of Aratana Therapeutics. "It is an endorsement of our strategy of identifying and developing compounds from human pharmaceutical and biotech companies and bringing approved products to the animal health market via out-licensing or partnering with major animal health companies."

Dr. Steven St. Peter, Aratana board chairman and managing director at MPM Capital, explained, "Everything about Aratana is innovative, from how we envisioned and started the company to our approach to drug development and how we involve new investors. Our investors share our vision and enthusiasm, and their support, along with the commitment of Aratana's board of directors, senior leadership and staff, are making our vision a reality."

About Aratana Therapeutics                                                                                                      

Aratana Therapeutics is an animal health drug development company uniquely positioned to deliver high quality new medicines for unmet needs in animal health. Aratana licenses and develops proprietary, patent-protected compounds acquired from human pharmaceutical and biotechnology companies and then out-licenses to or partners with major animal health companies for commercialization. For more information, please visit www.aratanatherapeutics.com.

CONTACT: David K. Rosen, DVM
President and COO
Aratana Therapeutics, Inc.
913-951-2130
drosen@aratanarx.com


'/>"/>
SOURCE Aratana Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Aratana Therapeutics Announces $20 Million Financing
2. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
3. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
4. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
5. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
6. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
7. Fate Therapeutics Strengthens Its iPSC Platform
8. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
9. Nile Therapeutics Reports 2011 Third Quarter Financial Results
10. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
11. Orexigen® Therapeutics Reports Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, ... second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical ... eBook by providing practical tips, tools, and strategies for clinical researchers. , “The ...
(Date:6/23/2016)... June 23, 2016 Houston Methodist Willowbrook ... Cy-Fair Sports Association to serve as their official ... Houston Methodist Willowbrook will provide sponsorship support, athletic ... with association coaches, volunteers, athletes and families. ... Cy-Fair Sports Association and to bring Houston Methodist ...
(Date:6/23/2016)... ... , ... Supplyframe, the Industry Network for electronics hardware design ... Located in Pasadena, Calif., the Design Lab’s mission is to bring together inventors ... and brought to market. , The Design Lab is Supplyframe’s physical representation of ...
(Date:6/23/2016)... 2016 Andrew D ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... from touchONCOLOGY, Andrew D Zelenetz , discusses ... care is placing an increasing burden on healthcare ... therapies. With the patents on many biologics expiring, ...
Breaking Biology Technology:
(Date:4/15/2016)... April 15, 2016  A new partnership announced ... accurate underwriting decisions in a fraction of the ... priced and high-value life insurance policies to consumers ... With Force Diagnostics, rapid testing (A1C, Cotinine ... readings (blood pressure, weight, pulse, BMI, and activity ...
(Date:3/31/2016)... RATON, Florida , March 31, 2016 ... LEGX ) ("LegacyXChange" or the "Company") ... for potential users of its soon to be launched ... video ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide ... the use of DNA technology to an industry that ...
(Date:3/22/2016)... 2016 According to ... for Consumer Industry by Type (Image, Motion, Pressure, ... & IT, Entertainment, Home Appliances, & Wearable ... 2022", published by MarketsandMarkets, the market for ... USD 26.76 Billion by 2022, at a ...
Breaking Biology News(10 mins):